Global Gardner Syndrome Treatment Market – Industry Trends and Forecast to 2030

Gardner Syndrome Treatment Market Analysis and Size

The incidence of gardner syndrome is around 1 per one million people within the U.S., with an occurrence of 1 in 8000 individuals.  Usually, gardner syndrome patients typically have epidermoid cysts. The major risk factor that comes with this condition is having at least one parent with the syndrome. People suffering from this syndrome also have a much higher risk of colon cancer.  

Data Bridge Market Research analyses a growth rate in the gardner syndrome treatment market in the forecast period 2023-2030. The expected CAGR of gardner syndrome treatment market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 18.6 billion in 2022, and it would grow up to USD 25.46 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gardner Syndrome Treatment Market Scope and Segmentation

Market Definition

Gardner syndrome is a rare genetic disorder which usually starts with the growth of benign cancer growth. The syndrome can cause growth on numerous regions in the body. The huge number of tumor is generally found in colon in large numbers. As the age of the individual rises, the tumors also surge in large numbers. This syndrome is caused because of the defect in adenomatous polyposis coli (APC) gene, that initiates the production of APC protein. The essential role of APC protein is to control the cell growth by avoiding the cells from rapid division.   

Gardner Syndrome Treatment Market Dynamics

Drivers

• Rising Cases of Colon Cancer

It can be said that the lifetime risk of developing colorectal cancer is around 1 in 23 (4.3%) for men and 1 in 25 (4.0%) for women. In the U.S., colorectal cancer is the third leading cause of cancer-associated deaths in men and in women, and it is the second most common cause of cancer deaths for both genders. It's anticipated to cause around 52,580 deaths during 2022. It has been witnessed that around 106,180 new cases of colon cancer (54,040 men and 52,140 women) and 44,850 new cases of rectal cancer (26,650 men and 18,200 women) existed in 2021. Thus, this increasing prevalence is demanding higher medications and thus boosting the market growth.

• Increased Diagnosis of Gardner Syndrome

Gardner Syndrome can be diagnosed either through medical examination, full evaluation of medical and familial history and self-reported symptoms, or endoscopy of the lower gastrointestinal (GI) tract. It can also be detected through molecular testing of the blood for screening of genetic mutations known to be linked to the disease. Pre-natal genetic testing can also be done, and if turns out to be positive, endoscopic screenings for polyps is recommended to start as early as 10 years of age. Thus, it boost the market growth.

Opportunities

• Increasing Treatment Methods

Gardner’s syndrome have a huge risk of developing colon cancer, thus the treatment is generally aimed at preventing this. Several medications such as an NSAID or a COX2 inhibitor (celecoxib) may be used to help restrict the growth of colon polyps. Furthermore, treatment also involves close monitoring of the polyps with lower GI tract endoscopy to prevent the malignancy. If 20 or more polyps exist, then it is advised that the colon must be removed to decrease the risk of colon cancer development. Therefore, all these treatment methods are boosting the growth of the market.

Restraints/Challenges

• Complications Associated with Endoscopy

There are many complications that are found to be associated with endoscopy. The complications include grogginess from the sedation, nausea, a feeling of bloating, difficulty swallowing, mild pain where the IV was inserted and sore throat. Thus, all these restrain the market growth.

• High Cost of Treatment

The enormous expenditure that is required for the surgeries and different treatment processes inhibits market growth. Numerous market players make some huge investments in manufacturing new and advanced treatment procedures to increase the recovery process, and in return, the cost is increased.

This gardner syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gardner syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Gardner Syndrome Treatment Market Scope

The gardner syndrome treatment market is segmented on the basis of cancer type, age and therapeutics. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

• Dilated Cardiomyopathy
• Skeletal Myopathy
• Neutropenia
• Others

Age

• 22 years
• 30-50 years

Therapeutics

• NSAIDS
• COX-2 Inhibitor

Gardner Syndrome Treatment Regional Analysis/Insights

The gardner syndrome treatment market is analyzed and market size insights and trends are provided by cancer type, age and therapeutics as referenced above.

The major countries covered in the gardner syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period because of the increased awareness among the population base about rare disorders including gardner syndrome and therapeutics.

Asia-Pacific is considered to grow over the coming years because of the increase in point of care diagnostics, novel therapeutics for treatment of the syndrome, huge opportunities in developing markets and different strategic initiatives by several market players.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Gardner Syndrome Treatment Share Analysis

The gardner syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gardner syndrome treatment market

Key players operating in the gardner syndrome treatment market include:

• Biochem Pharma (India)
• Zydus Group (India)
• Vernalis (R&D) Limited (U.K.)
• Sun Pharmaceutical Industries Ltd (India)
• Sanofi (France)
• Pfizer Inc (U.S.)
• GALDERMA LABORATORIES, L.P.(U.S.)
• Mayne Pharma Group Limited (Australia)
• Akorn Operating Company LLC (U.S.)
• Johnson & Johnson Services, Inc. (India)
• Medimetriks Pharmaceuticals, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)

SKU-60422